Neda Mehr, MD
Dermatology · Newport Beach, CANPI 1841432861
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.2%), consulting fees and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Solta Medical, A Division Of Bausch Health US, LLC at 44.2% of the total. Reporting peaked in 2022 at $7,163 and has fallen 87.2% since, to $915 in 2025.
Across 180 payments — averaging $71.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Solta Medical, A Division Of Bausch Health US, LLC$6K
- Merz North America, Inc.$4K
- AbbVie$1K
- Biofrontera Inc.$546
- Pfizer$366
- Lilly USA, LLC$284
- plus $1K from 14 others
What the payments were for
- Consulting fees$5,50043%
- Travel & lodging$30%
- Food & beverage$7,36557%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Solta Medical, A Division Of Bausch Health US, LLC | 10 | $5,693 |
| Merz North America, Inc. | 34 | $3,799 |
| AbbVie(2 entities) | 41 | $1,117 |
| Biofrontera Inc. | 32 | $546 |
| Pfizer | 17 | $366 |
| Lilly USA, LLC | 8 | $284 |
| Sanofi | 8 | $262 |
| Arcutis Biotherapeutics, Inc. | 5 | $259 |
| Novartis | 4 | $105 |
| Incyte Corporation | 4 | $101 |
| Galderma Laboratories, L.p. | 5 | $81 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| VYNE Pharmaceuticals Inc. | 2 | $37 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $37 |
| UCB, Inc. | 1 | $35 |
| LEO Pharma Inc. | 1 | $29 |
| Organon | 1 | $21 |
| EPI Health, LLC | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Strata Skin Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$1,811
- BOTOX COSMETIC$229
- OLUMIANT$119
How this compares
$12,881 in reported general payments places this provider in the 85th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 39 | $2,407 |
| Clobetasol Propionate | 60 | $1,660 |
| Ketoconazole | 46 | $780 |
| Ciclopirox | 28 | $579 |
| Minoxidil | 55 | $458 |
| Triamcinolone Acetonide | 18 | $177 |
| Mupirocin | 16 | $126 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Newport Beach
- Kevin BelascoNewport Beach$464K
- Navid NamiNewport Beach$302K
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.